Experimental treatment significantly slows progression of a fatal brain disease in women during clinical trial

MedicalXpress | أغس 02, 2026

Researchers at Tel Aviv University have presented new findings indicating that the experimental drug Davunetide may significantly slow the progression of progressive supranuclear palsy (PSP) in women, who exhibited a markedly different response to treatment than men. These results reinforce the need for sex-specific medicine in neurodegenerative diseases.